• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

News

Article

Daily Derm Times: March 19, 2025

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times logo

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Journal Digest: March 19

This review of the latest dermatologic studies includes insights into supporting laser tattoo removal for adults impacted by the justice-system, a case of blastic plasmacytoid dendritic cell neoplasm, and more.

Addressing the Challenges of Pigmentary Disorders in Women Across the Fitzpatrick Skin Spectrum

Valerie Harvey, MD, MPH, FAAD, discusses pigmentary disorders like melasma and hyperpigmentation, highlighting their disproportionate impact on women, particularly those with skin of color.

Multidisciplinary Approaches to Advanced BCC and CSCC

The expert discussion focused on patient management strategies, treatment modalities, and the role of multidisciplinary collaboration.

Patients and Providers Seek More Effective, Time-Saving Treatments for Seborrheic Dermatitis

According to a survey, both patients and clinicians are unsatisfied with the current therapeutic landscape and are looking for options that better fulfill patient needs.

Post Hoc Analysis Highlights Zasocitinib’s Efficacy Across Patient Groups

The investigational drug, designed using AI technology, optimizes pharmacologic characteristics for psoriasis treatment.

Novel Monopolar Radiofrequency Device is Effective and Safe for Facial Wrinkles

Participants experienced smoother, younger-looking skin after just 1 session, with results lasting up to 16 weeks.

Tezepelumab Shows Sustained Post-Treatment Benefit in Chronic Spontaneous Urticaria Despite Missed Primary Endpoint

Tezepelumab reduced CSU activity post-treatment through week 32, suggesting a delayed, sustained TSLP blockade effect.

© 2025 MJH Life Sciences

All rights reserved.